Avtor/Urednik		Giacobini, Ezio
Naslov		Present and future of cholinesterase inhibitors in the treatment of Alzheimer's disease
Prevedeni naslov		Sedanjost in prihodnost inhibitorjev holinesteraze v zdravljenju Alzheimerjeve bolezni
Tip		članek
Vir		In: Kogoj A, editor. Zdravljenje demenc: depresija in motnje spoznavnih sposobnost. Zbornik prispevkov 1. psihogeriatrično srečanje; 1998 nov 27-28; Kranjska Gora. Ljubljana: Združenje za pomoč pri demenci,
Leto izdaje		1998
Obseg		str. 16-9
Jezik		eng
Abstrakt		Presently, cholinesterase inhibitors (CHEIs) represent the drug of choice for the treatment of Alzheimer's disease (AD). Application of ADAS-cog scale in more than 30 phase III clinical trials that included over 6000 subjects from comparable patient population during a 6-month treatment period, demonstrated significant effects of three different reversible (tacrine, donepezil and galanthamine) and three pseudo-irreversible or irreversible CHEIs (eptastigmine, rivastigmine and metrifonate) on cognition. Clinical effect of most CHEIs in AD seems to be stabilisation of the patient symptomatology rather than improvement of the disease from base-line. In addition to positive effects on cognition, CHEIs produce significant effects on behaviour. They alleviated particularly such symptoms as apathy, motor agitation and hallucinations. Improvement of behavioural symptoms may translate into a better quality of life for both patient and his caregiver. Long-term studies have shown that clinical efficacy of CHEIs can be extended to 12 months or more.
Deskriptorji		ALZHEIMER'S DISEASE COGNITION DISORDERS CHOLINESTERASE INHIBITORS AGED PHYSOSTIGMINE MEMORY